A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries
worldwide for the treatment of hypertension. In China the usual recommended starting and
maintenance dose is 80 mg o.d. The combination of HCTZ 12.5 mg with valsartan 80 mg has been
shown to have additive effects in lowering blood pressure compared to valsartan 80 mg in
patients not adequately controlled by valsartan 80 mg monotherapy5 or in non-selected
patients6. This fixed combination is registered in most countries worldwide.
The potential benefits of these combinations should be evaluated in patients not adequately
controlled by valsartan 80 mg monotherapy. This study will compare the efficacy, safety and
tolerability of adding HCTZ 12.5 mg to valsartan 80 mg in those hypertensive patients.
This study is not recruiting in the US.